Inclusion Criteria:

          1. ≥18 and ≤75 years old while signing the informed consent;

          2. Sign an informed consent before undertaking any trial-related activities;

          3. Stage IIIb-IV NSCLC patients diagnosed by licensed pathologist, NY-ESO-1 positive
             cells >10% by IHC.

          4. Received at least one run of standard therapy(surgery, chemo, radiation and targeted
             therapy) or first line and second line treatment failure; If the patient has EGFR
             mutation or ALK gene rearrangement, they can be enrolled after the appropriate EGFR or
             ALK tyrosine kinase inhibitor treatment failed;

          5. Have one positive indication of the following immunological biomarkers during the
             screening stage: HLA-A*0201+, NYESO-1+;

          6. ECOG score 0-1(see appendix);Life expectancy is longer than 3 months;

          7. No Chinese herbal medicine usage within 4 weeks before enrollment;

          8. left ventricular ejection fraction≥50%

          9. Lab test results meet the following requirements:

             White blood cell count≥3.0×109/L; ANC≥1.5 ×109/L (No GCSF support); PLT≥75 ×109/L;
             Hemoglobin≥10g/dL (No transfusion in the last 7 days); Prothrombin time or INR ≤1.5×
             normal upper limit, except taking anticoagulant therapy; PTT≤1.5× normal upper limit,
             except taking Anticoagulant therapy;a 24-hour creatinine clearance rate≥60mL/ min;
             AST/SGOT≤2.5 ×ULN; ALT/SGPT≤2.5 ×ULN; ALP≤2.5 ×ULN; TBIL≤1.5×ULN (expect that the
             subject has Gilber's syndrome).

         10. Levels of calcium, potassium, and magnesium in serum are within the normal range;

         11. Pregnancy test is negative for female subjects with reproductive capability before
             participating the study；Female subjects must consent using birth control during the
             study or prohibit any homo or heterosexual behavior;

         12. Can regularly visit the research institutions for tests, evaluations, and monitoring
             throughout the study period.

        Exclusion Criteria:

          1. SCLC;

          2. Received major surgery, conventional chemotherapy, large-area radiotherapy, immune
             therapy or any biological anti-tumor therapy within 4 weeks prior to the study;

          3. Allergic to any components of the therapy;

          4. Never recovered to <2 grade CTCAE from prior surgery or treatment-related adverse
             events;

          5. With two types of primary solid tumors;

          6. Poorly managed hypertension (systolic blood pressure >160 mmHg and / or diastolic
             blood pressure > 90 mmHg) or clinically significant(for example, active)
             cardiovascular and cerebrovascular diseases such as cerebrovascular incident (within 6
             months prior to signing the informed consent), myocardial infarction (within 6 months
             prior to signing the informed consent), unstable angina, grade II or above heart
             failure according to New York Heart Association Grading (See Appendix) Congestive, or
             severe arrhythmia can not be controlled by medication or has a potential impact on the
             study; With consecutive three times of obvious abnormality on electrocardiogram or
             average QTc interval ≥450 ms;

          7. With other serious organic disease and/or mental illness;

          8. With systemic active infections that need treatments, including active tuberculosis,
             HIV-positive or clinically active hepatitis A, B and C;

          9. With autoimmune diseases: such as a history of inflammatory bowel disease (IBD) or
             other autoimmune diseases determined by the investigator to be unsuitable for the
             study (e.g. systemic lupus erythematosus (SLE), vasculitis, invasive pulmonary
             disease);

         10. Within 4 weeks prior the infusion, received chronic systemic steroid cortisone,
             Hydroxyurea, immunomodulatory treatment (for example: Interleukin 2, alpha or gamma
             interferon, GCSF, mTOR inhibitors, cyclosporine etc.);

         11. History of organ allografts, autologous / allogeneic stem cell transplantation, and
             renal replacement therapy;

         12. With central nervous system metastasis. Patients with neurological symptoms need a
             brain CT/MRI examination to rule out brain metastases;

         13. With uncontrolled diabetes, pulmonary fibrosis, interstitial lung disease, acute lung
             disease, or liver failure;

         14. History of alcohol and / or drug abuse;

         15. Pregnant or lactating female patients;

         16. Received concomitant medication prohibited by the protocol;

         17. With any medical condition or disease determined by the investigators that may be
             detrimental to this trial;

         18. No capacity or limited capacity to make juridical acts.